[Genetic mutation as a risk factor for a patient treated with warfarin].
Laine
Kari
K
Turun yliopiisto ja TYKS, kliininen farmakologia, Pharmacity, Turku. karlai@utu.fi
Lundgren
Stefan
S
Ketonen
Matti
M
D002637:Chest Pain / Q000175:diagnosis / Q000209:etiology; D001026:Coronary Artery Bypass / Q000379:methods; D005387:Finland; D005500:Follow-Up Studies; D006470:Hemorrhage / Q000139:chemically induced* / Q000235:genetics* / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000517:prevention & control / Q000601:surgery*; D010597:Pharmacogenetics; D017354:Point Mutation; D011183:Postoperative Complications / Q000139:chemically induced / Q000517:prevention & control; D011859:Radiography; D018570:Risk Assessment; D014859:Warfarin / Q000009:adverse effects* / Q000627:therapeutic use
D014859:Warfarin